IL-16 antagonist peptides and DNA encoding the peptides
The present invention has found that a series of peptides having sequences that substantially correspond to specific regions of the C-terminus of IL-16 can inhibit the activity of IL-16. The present invention has demonstrated that such IL-16-inhibiting peptides can be as short as 4 amino acids in length. Based on these discoveries, the present invention provides IL-16 antagonist peptides and the use thereof for the treatment of IL-16 mediated disorders such as certain inflammatory diseases.
1. An isolated nucleic acid molecule coding for an IL-16 antagonist peptide consisting of a sequence selected from the group consisting of RRTSLQCKQTTASADS (SEQ ID NO:34), RRASLQSKETTAAGDS (SEQ ID NO:35), RRKALQSKETTAAGDS (SEQ ID NO:36), RRTALQCKQTTASADS (SEQ ID NO:37) and RRASLQCKQTTASADS (SEQ ID NO:38).
2. A pharmaceutical composition comprising an isolated Interleukin-16 (IL-16) antagonist peptide and a pharmaceutically acceptable carrier, wherein said IL-16 antagonist peptide consists of a sequence selected from the group consisting of SEQ ID NOs: 17, 24 and 30.
3. A composition comprising an isolated Interleukin-16 (IL-16) antagonist peptide and a pharmaceutically acceptable carrier, wherein said IL-16 antagonist peptide consists of a sequence selected from the group consisting of SEQ ID NOS: 2–7, 9–11, 13–32 and 34–38.